

COMMISSION REGULATION (EC) No 1729/2006

of 23 November 2006

amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib and triclabendazole

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

include triclabendazole in that Annex for all ruminants for muscle, fat, liver and kidney, excluding animals producing milk for human consumption amending the maximum residue limits values.

Having regard to the Treaty establishing the European Community,

(4) Regulation (EEC) No 2377/90 should therefore be amended accordingly.

Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin⁽¹⁾, and in particular Article 2 and the third paragraph of Article 4 thereof,

(5) An adequate period should be allowed before the applicability of this Regulation in order to enable Member States to make any necessary adjustment in the light of this Regulation to the authorisations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products⁽²⁾.

Having regard to the opinions of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,

Whereas:

(6) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,

(1) All pharmacologically active substances used in the Community in veterinary medicinal products intended for food-producing animals should be evaluated in accordance with Regulation (EEC) No 2377/90.

HAS ADOPTED THIS REGULATION:

(2) Following examination of an application for the establishment of maximum residue limits for firocoxib in *Equidae* and in order to allow for the completion of minor scientific validation of studies, it is considered appropriate to include firocoxib in Annex III to Regulation (EEC) No 2377/90 for *Equidae* species.

Article 1

Annexes I and III to Regulation (EEC) No 2377/90 are amended in accordance with the Annex to this Regulation.

(3) The substance triclabendazole is included in Annex I to Regulation (EEC) No 2377/90 for bovine and ovine for muscle, kidney and liver, excluding animals producing milk for human consumption. Following examination of an application for the modification of those maximum residue limits, it is considered appropriate to

Article 2

This Regulation shall enter into force on the third day following its publication in the *Official Journal of the European Union*.

It shall apply from 21 January 2007.

⁽¹⁾ OJ L 224, 18.8.1990, p. 1. Regulation as last amended by Commission Regulation (EC) No 1451/2006 (OJ L 271, 30.9.2006, p. 37).

⁽²⁾ OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive 2004/28/EC (OJ L 136, 30.4.2004, p. 58).

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 23 November 2006.

For the Commission
Günter VERHEUGEN
Vice-President

ANNEX

A. The following substance is inserted in Annex I to Regulation (EEC) No 2377/90:

2. Antiparasitic agents
- 2.1. Agents acting against endoparasites
- 2.1.3. Benzimidazoles and pro-benzimidazoles

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues
Triclabendazole	Sum of extractable residues that may be oxidised to keto-triclabendazole	All ruminants ⁽¹⁾	225 µg/kg 100 µg/kg 250 µg/kg 150 µg/kg	Muscle Fat Liver Kidney

⁽¹⁾ Not for use in animals producing milk for human consumption.

B. The following substance is inserted in Annex III to Regulation (EEC) No 2377/90:

5. Anti-inflammatory agents
- 5.1. Non-steroidal anti-inflammatory agents
- 5.1.4. Sulfonated phenyl lactones

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues
Firocoxib ⁽¹⁾	Firocoxib	<i>Equidae</i>	10 µg/kg 15 µg/kg 60 µg/kg 10 µg/kg	Muscle Fat Liver Kidney

⁽¹⁾ Provisional MRLs expire on 1 July 2007.